Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TRPV6 | Q9H1D0 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.47 |
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | MC4R | P32245 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980525 | 0.82 | RECQL (0.52) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL12865056 | 0.81 | RECQL (0.54) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL4797625 | 0.81 | SIGMAR1 (0.69) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL6972705 | 0.81 | SIGMAR1 (0.55) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL8193615 | 0.81 | SIGMAR1 (0.55) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL1204089 | 0.80 | TRPV6 (0.58) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL7621111 | 0.80 | RECQL (0.50) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL6974039 | 0.79 | MC4R (0.58) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL3709310 | 0.79 | RECQL (0.70) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 | |
| SCHEMBL15088885 | 0.78 | SIGMAR1 (0.51) | SIGMAR1RECQLSMN1; SMN2TSHRTRPV6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1106614-B1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER (US) | 2004-01-07 | — | — | EP | disclosed |
| US-6444677-B2 | TREATMENT OF INFLAMMATION, CARDIOVASCULAR DISEASE, PAIN, ETC. | PFIZER INC. | 2002-09-03 | — | — | US | disclosed |
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | IKEDA TAKAFUMI (JP) | 2001-11-29 | — | — | US | disclosed |
| EP-1106614-A1 | 5-Membered heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | PFIZER INC. (US) | 2001-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010046993-A1 | 5-memberd heteroaryl substituted 1,4-dihydropyridine compounds as bradykinin antagonists | BDKRB1, BDKRB2, CNR2 | SIGMAR1 127/4885RECQL 2401/4885SMN1; SMN2 3038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.